Companies
Lyell Immunopharma
a late-stage clinical company advancing next-generation chimeric antigen receptor and TCR-T cell therapies, with a June 2026 safety update on LYL273 in relapsed solid tumours; its epigenetic reprogramming technology addresses T-cell exhaustion, the central obstacle in solid-tumour cell therapy.
- Country
- United States
- Ticker
- LYEL
TCR-T (LYL273)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $50 million equity private placement tranche closed in March 2026 | ir.lyell.com · globenewswire.com · sec.gov |
| Capacity | more than 1,200 CAR T-cell doses per year | ir.lyell.com · biospace.com · stocktitan.net |
| Regulatory approval | Fast Track designation for LYL273 for mCRC | ir.lyell.com · biospace.com · sec.gov · stocktitan.net |
| Regulatory approval | RMAT and Fast Track designations for ronde-cel for R/R LBCL | ir.lyell.com · biospace.com · sec.gov |
| Production site | LyFE Manufacturing Center (LyFE) in Bothell, Washington | ir.lyell.com · stocktitan.net |
| Revenue | $36,000 for the full year 2025 | ir.lyell.com · globenewswire.com · tickergate.com |
Independent sources: biospace.com · globenewswire.com · ir.lyell.com · sec.gov · stocktitan.net · tickergate.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| TCR therapy (T-cell receptor engineered T cells) | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.